COPENHAGEN, Dec 20 (Reuters) - The CEO of Danish

drugmaker Zealand Pharma said on Friday that the data

from Novo Nordisk's CagriSema study supported

Zealand's own monotherapy approach to cagrilintide.

"The data supports our monotherapy approach to cagrilintide

big time, even though CagriSema may have disappointed the

market," Zealand Pharma CEO Adam Steensberg told Reuters after

Novo Nordisk released its CagriSema data, sending Zealand shares

plunging 20%.